| Literature DB >> 34472678 |
Victor Laserna1, Daniel Abegg2, Cláudia F Afonso3, Esther M Martin4, Alexander Adibekian2, Peter Ravn4,5, Francisco Corzana6, Gonçalo J L Bernardes1,3.
Abstract
We describe maleic-acid derivatives as robust cysteine-selective reagents for protein labelling with comparable kinetics and superior stability relative to maleimides. Diamide and amido-ester derivatives proved to be efficient protein-labelling species with a common mechanism in which a spontaneous cyclization occurs upon addition to cysteine. Introduction of chlorine atoms in their structures triggers ring hydrolysis or further conjugation with adjacent residues, which results in conjugates that are completely resistant to retro-Michael reactions in the presence of biological thiols and human plasma. By controlling the microenvironment of the reactive site, we can control selectivity towards the hydrolytic pathway, forming homogeneous conjugates. The method is applicable to several scaffolds and enables conjugation of different payloads. The synthetic accessibility of these reagents and the mild conditions required for fast and complete conjugation together with the superior stability of the conjugates make this strategy an important alternative to maleimides in bioconjugation.Entities:
Keywords: Michael addition; bioconjugation; cysteine; irreversibility; maleimides
Mesh:
Substances:
Year: 2021 PMID: 34472678 PMCID: PMC8596790 DOI: 10.1002/anie.202108791
Source DB: PubMed Journal: Angew Chem Int Ed Engl ISSN: 1433-7851 Impact factor: 15.336
Scheme 1Synthesis of conjugates with linear succinamic acid linkages.
Figure 1Small molecule and Ub reaction with different maleic acid derivatives. a) Small molecule and protein reaction conditions; b) Conversions observed using conditions A or B; c) Structures of reagents 1—10. DMF=dimethyl formamide.
Scheme 2Regioselectivity of the cyclization step with compound 9.
Figure 2a) Conjugation reaction of reagents 11–14 with different Cys‐containing proteins. b) Representative snapshot derived from 0.5 μs MD simulations on conjugate HER2‐14. The RMSD value of the protein, relative to the first frame, is also shown. c) Conjugation reaction of Trastuzumab V205C, K207A with 14. d) Conjugation reaction of Fc fragments 274C and 289C with 14.